Consequently, GEM@PLGA@HM demonstrated potent anti-tumor effects against HER2+ tumors, potentially due to the synergistic impact of increased intracellular GEM delivery and the inhibition of the HER2-induced signaling pathway by the HER2-scFv. Here, ERBB2 is linked to neoplasm.